カテゴリ： Allied Market Research, 世界, 医療/バイオ

筋萎縮性側索硬化症治療のグローバル市場（2023-2032）：リルゾール、エダラボン、その他

■ 英語タイトル：Amyotrophic Lateral Sclerosis Treatment Market By Drugs (Riluzole, Edaravone, Others), By Type (Sporadic ALS, Familial ALS), By Distribution Channel (Hospital Pharmacies, Online Providers, Drug Stores and Retail Pharmacies): Global Opportunity Analysis and Industry Forecast, 2023-2032

調査会社Allied Market Research社が発行したリサーチレポート（データ管理コード：ALD23SEP115）■ 発行会社/調査会社：Allied Market Research
■ 商品コード：ALD23SEP115
■ 発行日：2023年4月
■ 調査対象地域：グローバル
■ 産業分野：生命科学
■ ページ数：260
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Online Only（1名閲覧、印刷不可）USD3,570 ⇒換算￥542,640見積依頼/購入/質問フォーム
Single User（1名閲覧）USD5,730 ⇒換算￥870,960見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）USD9,600 ⇒換算￥1,459,200見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Allied Market Research社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[筋萎縮性側索硬化症治療のグローバル市場（2023-2032）：リルゾール、エダラボン、その他]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

筋萎縮性側索硬化症治療市場は、2022年に6億6,225万ドルと評価され、2023年から2032年までの年平均成長率は4.6%を示し、2032年には10億3,894万ドルに達すると推定されます。 筋萎縮性側索硬化症はルー・ゲーリッグ病とも呼ばれ、脳や脊髄の神経細胞を侵す進行性の神経変性疾患です。筋萎縮性側索硬化症では、これらの神経細胞が徐々に破壊され死滅するため、筋肉のコントロールができなくなり、最終的には麻痺が生じます。筋萎縮性側索硬化症の症状は通常、手足の筋力低下やこわばりから始まり、徐々に体の他の部位に広がっていきます。その他の症状としては、会話、嚥下、呼吸の困難、筋肉のけいれんや痙攣などがあります。現在、筋萎縮性側索硬化症を完治させる治療法はなく、治療は主に症状の管理と生活の質の向上に重点が置かれています。  

筋萎縮性側索硬化症の治療によく使われる薬には、リルゾール、エダラボン、フェニル酪酸ナトリウム、タウルソジオなどがあります。リルゾールは、運動ニューロンを損傷する神経伝達物質であるグルタミン酸の放出を抑えることで作用し、エダラボンは、運動ニューロンを損傷する体内の酸化ストレスを軽減することで作用するフリーラジカルスカベンジャーです。  

世界の筋萎縮性側索硬化症治療薬市場の成長を促進する主な要因は、筋萎縮性側索硬化症の有病率の増加、筋萎縮性側索硬化症に対する新薬や治療法の承認の増加などです。筋萎縮性側索硬化症の罹患率は、世界人口の高齢化に伴って上昇すると予想されており、そのため、症状を管理し、病気の進行を遅らせるのに役立つ可能性のある治療薬や療法に対する需要が増加しています。  
また、医療従事者、患者、介護者の間で筋萎縮性側索硬化症に対する認識と理解が高まっていることも市場を牽引しています。筋萎縮性側索硬化症に関する研究が進み、医療技術が進歩したことで、筋萎縮性側索硬化症の根本的なメカニズムや潜在的な治療標的に対する理解が深まっています。このため、遺伝子治療や幹細胞治療などの新しい治療法が開発され、予測期間中の市場成長が期待されています。  

さらに、規制の枠組みや償還政策も筋萎縮性側索硬化症治療薬市場に影響を与える可能性があります。米国FDAなどの規制機関による新薬や治療法の承認は、患者に新しく革新的な治療法を提供することで市場の成長を促進する可能性があります。例えば、筋萎縮性側索硬化症の治療薬としてTofersen、ANX005などのパイプライン製品が増加し、市場プレイヤーに有利な機会を提供すると予想されています。また、これらの治療に対する保険適用を提供する償還政策も、患者にとってよりアクセスしやすく、手頃な価格にすることで、市場の拡大に役立ちます。  

しかし、筋萎縮性側索硬化症という病気に対する理解が限定的であること、筋萎縮性側索硬化症の新しい治療法を承認するための規制プロセスが厳格であるため、患者のための新しい治療法の利用が遅れる可能性があること、治療費が高くなることなどが、市場の成長を制限する可能性があります。

筋萎縮性側索硬化症治療薬市場は薬剤、タイプ、流通チャネル、地域に区分されます。薬剤ベースでは、市場はリルゾール、エダラボン、その他に分類されます。タイプ別では、市場は散発性筋萎縮性側索硬化症と家族性筋萎縮性側索硬化症に二分されます。流通チャネル別では、病院薬局、オンラインプロバイダー、ドラッグストア・小売薬局に分類されます。地域別では、北米（米国、カナダ、メキシコ）、欧州（ドイツ、フランス、英国、イタリア、スペイン、その他欧州）、アジア太平洋（日本、中国、インド、オーストラリア、韓国、その他アジア太平洋）、LAMEA（ブラジル、南アフリカ、サウジアラビア、その他LAMEA）に分析されます。 

世界の筋萎縮性側索硬化症治療薬市場で事業を展開する主な主要企業は、Aquestive Therapeutics, Inc., Glenmark Pharmaceuticals Limited, Sun Pharmaceutical Industries Ltd., Viatris Inc., Amylyx Pharmaceuticals, Inc., Mitsubishi Chemical Group Corporation,  Otsuka Pharmaceutical Co., Ltd., Covis Pharma GmbH, ITALFARMACO S.p.A., and Alkem Laboratories Ltdなどです。同市場で事業を展開する主要企業は、製品ポートフォリオを拡大するための主要戦略として、製品承認、契約、製品上市を採用しています。例えば、2023年1月、Amylyx Pharmaceuticals, Inc.は、イスラエル、ガザ、ヨルダン川西岸、パレスチナにおける筋萎縮性側索硬化症治療薬AMX0035（フェニル酪酸ナトリウムおよびウルソドキシコルタウリン）の規制当局の審査および承認に向けて、Neopharm社が製品化することを想定した独占的ライセンスおよび販売契約をNeopharm社と締結したと発表しました。

ステークホルダーにとっての主な利点
本レポートは、筋萎縮性側索硬化症治療市場の市場機会を特定するために、2022年から2032年までの筋萎縮性側索硬化症治療市場分析の市場セグメント、現在の動向、予測、ダイナミクスの定量的分析を提供します。
筋萎縮性側索硬化症治療の市場機会を特定します。
ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益志向のビジネス決定を行い、サプライヤーとバイヤーのネットワークを強化できるようにします。
筋萎縮性側索硬化症治療薬市場のセグメンテーションを詳細に分析することで、市場機会を見極めることができます。
筋萎縮性側索硬化症治療薬市場の細分化に関する詳細な分析により、市場機会を見極めることができます。
市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
筋萎縮性側索硬化症治療薬の地域別および世界市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析を含みます。

主要市場セグメント
薬剤別
リルゾール
エダラボン
その他

タイプ別
散発性筋萎縮性側索硬化症
家族性筋萎縮性側索硬化症

販売チャネル別
病院薬局
オンラインプロバイダー
ドラッグストアと小売薬局

地域別
北米
米国
カナダ
メキシコ
ヨーロッパ
ドイツ
フランス
イギリス
イタリア
スペイン
その他のヨーロッパ
アジア太平洋
日本
中国
オーストラリア
インド
韓国
その他のアジア太平洋地域
LAMEA
ブラジル
サウジアラビア
南アフリカ
その他の地域

主な市場プレイヤー
○ Alkem Laboratories Ltd
○ Amylyx Pharmaceutic筋萎縮性側索硬化症, Inc.
○ Aquestive Therapeutics, Inc.
○ Covis Pharma GmbH
○ Glenmark Pharmaceutic筋萎縮性側索硬化症 Limited
○ ITALFARMACO S.p.A.
○ Mitsubishi Chemical Group Corporation
○ Otsuka Pharmaceutical Co., Ltd.
○ Sun Pharmaceutical Industries Ltd.
○ Viatris Inc.

第1章：イントロダクション
第2章：エグゼクティブサマリー
第3章：市場概要
第4章：筋萎縮性側索硬化症治療市場、薬剤別
第5章：筋萎縮性側索硬化症治療市場、タイプ別
第6章：筋萎縮性側索硬化症治療市場、流通チャネル別
第7章：筋萎縮性側索硬化症治療市場、地域別
第8章：競争状況
第9章：企業情報

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Bargaining power of suppliers
3.3.2. Bargaining power of buyers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Growth in awareness and understanding of ALS
3.4.1.2. Increase in prevalence of amyotrophic lateral sclerosis
3.4.1.3. Initiatives by government and non-government organizations

3.4.2. Restraints
3.4.2.1. Side effects of drugs

3.4.3. Opportunities
3.4.3.1. Increase in R&D activities

3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS
4.1. Overview
4.1.1. Market size and forecast
4.2. Riluzole
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Edaravone
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Others
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
CHAPTER 5: AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Sporadic ALS
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Familial ALS
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
CHAPTER 6: AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital Pharmacies
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Online Providers
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Drug Stores and Retail Pharmacies
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Drugs
7.2.3. Market size and forecast, by Type
7.2.4. Market size and forecast, by Distribution Channel
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Drugs
7.2.5.1.3. Market size and forecast, by Type
7.2.5.1.4. Market size and forecast, by Distribution Channel
7.2.5.2. Canada
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Drugs
7.2.5.2.3. Market size and forecast, by Type
7.2.5.2.4. Market size and forecast, by Distribution Channel
7.2.5.3. Mexico
7.2.5.3.1. Key market trends, growth factors and opportunities
7.2.5.3.2. Market size and forecast, by Drugs
7.2.5.3.3. Market size and forecast, by Type
7.2.5.3.4. Market size and forecast, by Distribution Channel
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Drugs
7.3.3. Market size and forecast, by Type
7.3.4. Market size and forecast, by Distribution Channel
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Drugs
7.3.5.1.3. Market size and forecast, by Type
7.3.5.1.4. Market size and forecast, by Distribution Channel
7.3.5.2. France
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Drugs
7.3.5.2.3. Market size and forecast, by Type
7.3.5.2.4. Market size and forecast, by Distribution Channel
7.3.5.3. UK
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Drugs
7.3.5.3.3. Market size and forecast, by Type
7.3.5.3.4. Market size and forecast, by Distribution Channel
7.3.5.4. Italy
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Drugs
7.3.5.4.3. Market size and forecast, by Type
7.3.5.4.4. Market size and forecast, by Distribution Channel
7.3.5.5. Spain
7.3.5.5.1. Key market trends, growth factors and opportunities
7.3.5.5.2. Market size and forecast, by Drugs
7.3.5.5.3. Market size and forecast, by Type
7.3.5.5.4. Market size and forecast, by Distribution Channel
7.3.5.6. Rest of Europe
7.3.5.6.1. Key market trends, growth factors and opportunities
7.3.5.6.2. Market size and forecast, by Drugs
7.3.5.6.3. Market size and forecast, by Type
7.3.5.6.4. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Drugs
7.4.3. Market size and forecast, by Type
7.4.4. Market size and forecast, by Distribution Channel
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Drugs
7.4.5.1.3. Market size and forecast, by Type
7.4.5.1.4. Market size and forecast, by Distribution Channel
7.4.5.2. China
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Drugs
7.4.5.2.3. Market size and forecast, by Type
7.4.5.2.4. Market size and forecast, by Distribution Channel
7.4.5.3. Australia
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Drugs
7.4.5.3.3. Market size and forecast, by Type
7.4.5.3.4. Market size and forecast, by Distribution Channel
7.4.5.4. India
7.4.5.4.1. Key market trends, growth factors and opportunities
7.4.5.4.2. Market size and forecast, by Drugs
7.4.5.4.3. Market size and forecast, by Type
7.4.5.4.4. Market size and forecast, by Distribution Channel
7.4.5.5. South Korea
7.4.5.5.1. Key market trends, growth factors and opportunities
7.4.5.5.2. Market size and forecast, by Drugs
7.4.5.5.3. Market size and forecast, by Type
7.4.5.5.4. Market size and forecast, by Distribution Channel
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Key market trends, growth factors and opportunities
7.4.5.6.2. Market size and forecast, by Drugs
7.4.5.6.3. Market size and forecast, by Type
7.4.5.6.4. Market size and forecast, by Distribution Channel
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Drugs
7.5.3. Market size and forecast, by Type
7.5.4. Market size and forecast, by Distribution Channel
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Drugs
7.5.5.1.3. Market size and forecast, by Type
7.5.5.1.4. Market size and forecast, by Distribution Channel
7.5.5.2. Saudi Arabia
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Drugs
7.5.5.2.3. Market size and forecast, by Type
7.5.5.2.4. Market size and forecast, by Distribution Channel
7.5.5.3. South Africa
7.5.5.3.1. Key market trends, growth factors and opportunities
7.5.5.3.2. Market size and forecast, by Drugs
7.5.5.3.3. Market size and forecast, by Type
7.5.5.3.4. Market size and forecast, by Distribution Channel
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Key market trends, growth factors and opportunities
7.5.5.4.2. Market size and forecast, by Drugs
7.5.5.4.3. Market size and forecast, by Type
7.5.5.4.4. Market size and forecast, by Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. Amylyx Pharmaceuticals, Inc.
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.1.7. Key strategic moves and developments
9.2. Aquestive Therapeutics, Inc.
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.3. Covis Pharma GmbH
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.4. Glenmark Pharmaceuticals Limited
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.5. ITALFARMACO S.p.A.
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.6. Mitsubishi Chemical Group Corporation
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.6.7. Key strategic moves and developments
9.7. Sun Pharmaceutical Industries Ltd.
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.8. Viatris Inc.
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.9. Alkem Laboratories Ltd
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.10. Otsuka Pharmaceutical Co., Ltd.
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio

LIST OF TABLES
TABLE 01. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
TABLE 02. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR RILUZOLE, BY REGION, 2022-2032 ($MILLION)
TABLE 03. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR EDARAVONE, BY REGION, 2022-2032 ($MILLION)
TABLE 04. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 05. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 06. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR SPORADIC ALS, BY REGION, 2022-2032 ($MILLION)
TABLE 07. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR FAMILIAL ALS, BY REGION, 2022-2032 ($MILLION)
TABLE 08. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 09. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 10. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
TABLE 11. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 12. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 13. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
TABLE 14. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 15. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 16. NORTH AMERICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 17. U.S. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
TABLE 18. U.S. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 19. U.S. AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 20. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
TABLE 21. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 22. CANADA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 23. MEXICO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
TABLE 24. MEXICO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 25. MEXICO AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 26. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
TABLE 27. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 28. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 29. EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 30. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
TABLE 31. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 32. GERMANY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 33. FRANCE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
TABLE 34. FRANCE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 35. FRANCE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 36. UK AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
TABLE 37. UK AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 38. UK AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 39. ITALY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
TABLE 40. ITALY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 41. ITALY AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 42. SPAIN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
TABLE 43. SPAIN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 44. SPAIN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 45. REST OF EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
TABLE 46. REST OF EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 47. REST OF EUROPE AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 48. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
TABLE 49. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 50. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 51. ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 52. JAPAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
TABLE 53. JAPAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 54. JAPAN AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 55. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
TABLE 56. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 57. CHINA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 58. AUSTRALIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
TABLE 59. AUSTRALIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 60. AUSTRALIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 61. INDIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
TABLE 62. INDIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 63. INDIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 64. SOUTH KOREA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
TABLE 65. SOUTH KOREA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 66. SOUTH KOREA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 67. REST OF ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
TABLE 68. REST OF ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 69. REST OF ASIA-PACIFIC AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 70. LAMEA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
TABLE 71. LAMEA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 72. LAMEA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 73. LAMEA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 74. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
TABLE 75. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 76. BRAZIL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 77. SAUDI ARABIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
TABLE 78. SAUDI ARABIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 79. SAUDI ARABIA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 80. SOUTH AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
TABLE 81. SOUTH AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 82. SOUTH AFRICA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 83. REST OF LAMEA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
TABLE 84. REST OF LAMEA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 85. REST OF LAMEA AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 86. AMYLYX PHARMACEUTICALS, INC.: KEY EXECUTIVES
TABLE 87. AMYLYX PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
TABLE 88. AMYLYX PHARMACEUTICALS, INC.: PRODUCT SEGMENTS
TABLE 89. AMYLYX PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
TABLE 90. AMYLYX PHARMACEUTICALS, INC.: KEY STRATERGIES
TABLE 91. AQUESTIVE THERAPEUTICS, INC.: KEY EXECUTIVES
TABLE 92. AQUESTIVE THERAPEUTICS, INC.: COMPANY SNAPSHOT
TABLE 93. AQUESTIVE THERAPEUTICS, INC.: PRODUCT SEGMENTS
TABLE 94. AQUESTIVE THERAPEUTICS, INC.: PRODUCT PORTFOLIO
TABLE 95. COVIS PHARMA GMBH: KEY EXECUTIVES
TABLE 96. COVIS PHARMA GMBH: COMPANY SNAPSHOT
TABLE 97. COVIS PHARMA GMBH: PRODUCT SEGMENTS
TABLE 98. COVIS PHARMA GMBH: PRODUCT PORTFOLIO
TABLE 99. GLENMARK PHARMACEUTICALS LIMITED: KEY EXECUTIVES
TABLE 100. GLENMARK PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT
TABLE 101. GLENMARK PHARMACEUTICALS LIMITED: PRODUCT SEGMENTS
TABLE 102. GLENMARK PHARMACEUTICALS LIMITED: PRODUCT PORTFOLIO
TABLE 103. ITALFARMACO S.P.A.: KEY EXECUTIVES
TABLE 104. ITALFARMACO S.P.A.: COMPANY SNAPSHOT
TABLE 105. ITALFARMACO S.P.A.: PRODUCT SEGMENTS
TABLE 106. ITALFARMACO S.P.A.: PRODUCT PORTFOLIO
TABLE 107. MITSUBISHI CHEMICAL GROUP CORPORATION: KEY EXECUTIVES
TABLE 108. MITSUBISHI CHEMICAL GROUP CORPORATION: COMPANY SNAPSHOT
TABLE 109. MITSUBISHI CHEMICAL GROUP CORPORATION: PRODUCT SEGMENTS
TABLE 110. MITSUBISHI CHEMICAL GROUP CORPORATION: PRODUCT PORTFOLIO
TABLE 111. MITSUBISHI CHEMICAL GROUP CORPORATION: KEY STRATERGIES
TABLE 112. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
TABLE 113. SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 114. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
TABLE 115. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 116. VIATRIS INC.: KEY EXECUTIVES
TABLE 117. VIATRIS INC.: COMPANY SNAPSHOT
TABLE 118. VIATRIS INC.: PRODUCT SEGMENTS
TABLE 119. VIATRIS INC.: PRODUCT PORTFOLIO
TABLE 120. ALKEM LABORATORIES LTD: KEY EXECUTIVES
TABLE 121. ALKEM LABORATORIES LTD: COMPANY SNAPSHOT
TABLE 122. ALKEM LABORATORIES LTD: PRODUCT SEGMENTS
TABLE 123. ALKEM LABORATORIES LTD: PRODUCT PORTFOLIO
TABLE 124. OTSUKA PHARMACEUTICAL CO., LTD.: KEY EXECUTIVES
TABLE 125. OTSUKA PHARMACEUTICAL CO., LTD.: COMPANY SNAPSHOT
TABLE 126. OTSUKA PHARMACEUTICAL CO., LTD.: PRODUCT SEGMENTS
TABLE 127. OTSUKA PHARMACEUTICAL CO., LTD.: PRODUCT PORTFOLIO

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • てんかん治療薬のグローバル市場（2023-2032）：局所発作、全般発作、非てんかん発作
  • ジェネリック医薬品のグローバル市場（2023-2032）：心血管、感染症、がん、糖尿病、その他
  • 抗肥満薬のグローバル市場（2023-2032）：処方薬、市販薬
  • API中間体のグローバル市場（2023-2032）：API中間体、化学中間体
  • 血栓溶解薬のグローバル市場（2023-2032）：血栓溶解薬、抗血小板薬、抗凝固薬、その他
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(ALD23SEP115 )"筋萎縮性側索硬化症治療のグローバル市場（2023-2032）：リルゾール、エダラボン、その他" (英文：Amyotrophic Lateral Sclerosis Treatment Market By Drugs (Riluzole, Edaravone, Others), By Type (Sporadic ALS, Familial ALS), By Distribution Channel (Hospital Pharmacies, Online Providers, Drug Stores and Retail Pharmacies): Global Opportunity Analysis and Industry Forecast, 2023-2032)はAllied Market Research社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。